Stocks · News reference
Tiziana Life Sciences shares are trading higher after the company announced quantitative PET imaging results from the third patient with Multiple System Atrophy in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 1:55 PM
- Checked
- Jul 31, 2026, 1:54 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 667,000 Common Shares At $1.00 Per Share, Raising Total Holding To 4,472,261 Shares
Read original at benzingaTiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition
Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.
Read original at benzinga